Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes

Clinical and Translational Imaging

Volumn 3, Issue 1, 2015, Pages 57-64

  Frey, Kirk A ^a,b   Petrou, Myria ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amyloid PET; Dementia with Lewy bodies; Lewy body disease; Parkinson disease; Parkinson disease with dementia; PIB; Pittsburgh compound B

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLORBETABEN; FLORBETAPIR F 18;

AGING; ALZHEIMER DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; HUMAN; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PARKINSONIAN DEMENTIA SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 84942103781     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-015-0104-4     Document Type: Review

References (65)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392
4. Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115(4):409–415
5. Zaccai J, McCracken C, Brayne C (2005) A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34(6):561–566
6. Boot B (2013) The incidence and prevalence of dementia with Lewy bodies is underestimated. Psychol Med 43(12):2687–2688
7. Vann Jones SA, O’Brien JT (2014) The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 44(4):673–683
8. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop (1996). Neurology 47(5):1113–1124
9. McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on dementia with Lewy bodies. Neurology 53(5):902–905
10. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65(12):1863–1872
11. Yoshizawa H, Vonsattel JP, Honig LS (2013) Early neuropsychological discriminants for Lewy body disease: an autopsy series. J Neurol Neurosurg Psychiatry 84(12):1326–1330
12. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM (2011) Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 82(9):1033–1037
13. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11):812–819
14. Mosimann UP, Rowan EN, Partington CE, Collerton D, Littlewood E, O’Brien JT, Burn DJ, McKeith IG (2006) Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry 14:153–160
15. Suzuki M, Desmond TJ, Albin RL, Frey KA (2002) Striatal monoaminergic terminals in Lewy body and Alzheimer’s dementias. Ann Neurol 51(6):767–771
16. Tsuboi Y, Uchikado H, Dickson DW (2007) Neuropathology of Parkinson’s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 13(Suppl 3):S221–S224
17. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
18. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117(6):613–634
19. Braak H, Braak E (1990) Cognitive impairment in Parkinson’s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm Park Dis Dement Sect 2(1):45–57
20. Dickson DW (2002) Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol 15(4):210–216
21. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64(8):1404–1410
22. Oinas M, Sulkava R, Polvikoski T, Kalimo H, Paetau A (2007) Reappraisal of a consecutive autopsy series of patients with primary degenerative dementia: Lewy-related pathology. APMIS 115(7):820–827
23. Lowe J (2008) Neuropathology of dementia with Lewy bodies. Handb Clin Neurol 89:321–330
24. Jellinger KA (2009) Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 24:114–125
25. Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E (2010) Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neurosci Lett 485(3):222–227
26. Halliday GM, Holton JL, Revesz T, Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122(2):187–204
27. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134(Pt 5):1493–1505
28. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598
29. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
30. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA (2011) Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 134(Pt 6):1647–1657
31. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA (2008) Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4(1 Suppl 1):S67–S76
32. Rowe CC, Villemagne VL (2011) Brain amyloid imaging. J Nucl Med 52(11):1733–1740
33. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306–319
34. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O’Brien RJ, Wong DF, Troncoso JC, Resnick SM (2011) In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 68(2):232–240
35. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, Sherwin P, McLain R, Arnold SE (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68(11):1398–1403
36. Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL (2009) Amyloid imaging in Alzheimer’s disease and other dementias. Brain Imaging Behav 3(3):246–261
37. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73(10):754–760
38. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67(1):122–131
39. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM, Boeve BF, Senjem ML, Vemuri P, Petersen RC, Jack CR Jr (2012) Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 79(15):1570–1577
40. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31(8):1275–1283
41. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74(6):905–913
42. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM (2012) Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol 11(12):1057–1065
43. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O’Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68(20):1718–1725
44. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O’Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79(12):1331–1338
45. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71(12):903–910
46. Johansson A, Savitcheva I, Forsberg A, Engler H, Langstrom B, Nordberg A, Askmark H (2008) [(11)C]-PIB imaging in patients with Parkinson’s disease: preliminary results. Parkinsonism Relat Disord 14(4):345–347
47. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D (2008) [11C]PIB binding in Parkinson’s disease dementia. NeuroImage 39(3):1027–1033
48. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34(1):107–112
49. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ (2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74(1):77–84
50. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, Hershey T, Perlmutter JS (2010) Amyloid imaging of Lewy body-associated disorders. Mov Disord 25(15):2516–2523
51. Jokinen P, Scheinin N, Aalto S, Nagren K, Savisto N, Parkkola R, Rokka J, Haaparanta M, Roytta M, Rinne JO (2010) [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Parkinsonism Relat Disord 16(10):666–670
52. Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA (2011) Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord 17(3):160–165
53. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52(8):1210–1217
54. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH (2012) Brain amyloid and cognition in Lewy body diseases. Mov Disord 27(8):965–973
55. Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, Vemuri P, Senjem ML, Smith GE, Knopman DS, Lowe V, Jack CR Jr, Petersen RC, Kantarci K (2012) Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 135(Pt 8):2470–2477
56. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, Dickson DW, Parisi JE, Knopman DS, Smith GE, Ferman TJ, Petersen RC, Jack CR Jr (2012) Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 33(9):2091–2105
57. Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA (2012) Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79(11):1161–1167
58. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80(1):85–91
59. Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, Windhorst AD, Handels RL, Wolfs CA, Aalten P, Verhey FR, Verbeek MM, van Buchem MA, Hoekstra OS, Lammertsma AA, Scheltens P, van Berckel BN (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 9(4):414–421
60. Shimada H, Shinotoh H, Hirano S, Miyoshi M, Sato K, Tanaka N, Ota T, Fukushi K, Irie T, Ito H, Higuchi M, Kuwabara S, Suhara T (2013) Beta-amyloid in Lewy body disease is related to Alzheimer’s disease-like atrophy. Mov Disord 28(2):169–175
61. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67(1):122–131
62. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM, Boeve BF, Senjem ML, Vemuri P, Petersen RC, Jack CR Jr (2012) Indicators of amyloid burden in a population based study of cognitively normal elderly. Neurology 79(15):1570–1577
63. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31(8):1275–1283
64. Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM (2014) Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers. J Nucl Med 55:1397–1400
65. Shah M, Catafau AM (2014) Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med 55:871–874